Insider trading

Period: 12 months Stock: ELVN Type of trade: Sold × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

38 decisions over 12 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

38 decisions over 12 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

38 decisions over 12 months Remove this filter
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

38 decisions over 12 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
38 decisions over 12 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
38 decisions over 12 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

38 decisions over 12 months
Stock
Insider
Type ?
Why it stands out
1 Oct 2026
Garland J. Scott Director
Sold at will
$606.72K 13,000 at 46.67
100%
Sold half or more
17 Sep 2026
Hohl Benjamin CHIEF FINANCIAL OFFICER
Sold on a plan 3×
$303.00K 6,018 at 50.35
13.7%
Planned (10b5-1)
17 Sep 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan 3×
$251.75K 5,000 at 50.35
16.7%
Planned (10b5-1)
17 Aug 2026
Hohl Benjamin CHIEF FINANCIAL OFFICER
Sold on a plan 2×
$352.55K 6,018 at 58.58
13.1%
Planned (10b5-1)
17 Aug 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan 2×
$292.93K 5,000 at 58.59
16.7%
Planned (10b5-1)
4 Aug 2026
Derynck Mika K Director
Sold on a plan
$9.56M 158,795 at 60.21
100%
Sold half or more
17 Jul 2026
Hohl Benjamin CHIEF FINANCIAL OFFICER
Sold on a plan 5×
$316.78K 6,018 at 52.64
11.6%
Planned (10b5-1)
17 Jul 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan 5×
$263.37K 5,000 at 52.67
16.7%
Planned (10b5-1)
6 Jul 2026
Kunkel Lori Anne Director
Sold on a plan 2×
$504.90K 10,000 at 50.49
19.3%
Planned (10b5-1)
22 Jun 2026
ORBIMED ADVISORS LLC 10% owner · indirect
Sold at will 4×
$39.01M 860,123 at 45.36
79.7%
Sold half or more
17 Jun 2026
Hohl Benjamin CHIEF FINANCIAL OFFICER
Sold on a plan 3×
$263.58K 6,018 at 43.80
10.6%
Planned (10b5-1)
17 Jun 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan 3×
$219.02K 5,000 at 43.80
16.7%
Planned (10b5-1)
15 Jun 2026
ORBIMED ADVISORS LLC 10% owner · indirect
Sold at will 2×
$12.67M 281,408 at 45.02
53.4%
Sold half or more
5 Jun 2026
Kunkel Lori Anne Director
Sold on a plan 3×
$345.35K 10,000 at 34.54
16.2%
Planned (10b5-1)
18 May 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan 3×
$198.97K 5,000 at 39.79
16.7%
Planned (10b5-1)
17 Apr 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan 3×
$238.35K 5,000 at 47.67
16.7%
Planned (10b5-1)
25 Mar 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan
$1.40M 40,000 at 35.10
61.5%
Sold half or more
17 Mar 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan
$138.80K 5,000 at 27.76
16.7%
Planned (10b5-1)
10 Mar 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan
$305.83K 10,129 at 30.19
28.8%
Planned (10b5-1)
9 Mar 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan
$896.81K 29,871 at 30.02
54.4%
Sold half or more
6 Mar 2026
Hohl Benjamin CHIEF FINANCIAL OFFICER
Sold at will
$295.84K 10,000 at 29.58
16.4%
Not planned
17 Feb 2026
Collins Helen Louise CHIEF MEDICAL OFFICER
Sold on a plan
$1.18M 45,000 at 26.17
64.3%
Sold half or more
17 Feb 2026
Heyman Richard A. Director · indirect
Sold on a plan
$32.20K 1,230 at 26.18
5.2%
Planned (10b5-1)
6 Feb 2026
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER · indirect
Sold on a plan
$145.22K 5,000 at 29.04
0.7%
Planned (10b5-1)
20 Jan 2026
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER · indirect
Sold on a plan 2×
$535.10K 20,000 at 26.75
2.6%
Planned (10b5-1)
20 Jan 2026
Heyman Richard A. Director · indirect
Sold on a plan 2×
$32.90K 1,230 at 26.75
4.9%
Planned (10b5-1)
9 Jan 2026
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER · indirect
Sold on a plan 2×
$2.48M 91,198 at 27.22
10.6%
Planned (10b5-1)
9 Jan 2026
Patel Anish CHIEF OPERATING OFFICER · indirect
Sold on a plan 2×
$1.35M 48,300 at 27.99
18.3%
Planned (10b5-1)
9 Jan 2026
Heyman Richard A. Director · indirect
Sold on a plan
$107.13K 4,285 at 25.00
14.6%
Planned (10b5-1)
8 Jan 2026
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER · indirect
Sold on a plan 2×
$993.44K 41,302 at 24.05
4.6%
Planned (10b5-1)
8 Jan 2026
Heyman Richard A. Director · indirect
Sold on a plan 2×
$241.16K 9,635 at 25.03
27.4%
Planned (10b5-1)
19 Dec 2025
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER · indirect
Sold on a plan
$84.21K 5,000 at 16.84
0.6%
Planned (10b5-1)
8 Dec 2025
Patel Anish CHIEF OPERATING OFFICER · indirect
Sold on a plan 2×
$140.07K 6,663 at 21.02
2.5%
Planned (10b5-1)
19 Nov 2025
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER · indirect
Sold on a plan 2×
$279.15K 12,500 at 22.33
1.4%
Planned (10b5-1)
17 Nov 2025
Kintz Samuel PRESIDENT AND CEO · indirect
Sold on a plan
$272.74K 12,500 at 21.82
1.4%
Planned (10b5-1)
7 Nov 2025
Patel Anish CHIEF OPERATING OFFICER · indirect
Sold on a plan 2×
$116.03K 6,667 at 17.40
2.4%
Planned (10b5-1)
20 Oct 2025
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER · indirect
Sold on a plan
$276.03K 12,500 at 22.08
1.3%
Planned (10b5-1)
17 Oct 2025
Kintz Samuel PRESIDENT AND CEO · indirect
Sold on a plan
$266.65K 12,500 at 21.33
1.4%
Planned (10b5-1)
Showing 1–38 of 38.